BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 202,300 shares, an increase of 113.4% from the January 31st total of 94,800 shares. Based on an average daily trading volume, of 373,300 shares, the short-interest ratio is currently 0.5 days. Approximately 5.9% of the shares of the company are short sold.

Institutional Trading of BriaCell Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of BCTX. Vontobel Holding Ltd. increased its holdings in shares of BriaCell Therapeutics by 37.5% in the fourth quarter. Vontobel Holding Ltd. now owns 110,000 shares of the company’s stock worth $62,000 after purchasing an additional 30,000 shares during the period. Virtu Financial LLC bought a new stake in BriaCell Therapeutics during the fourth quarter valued at $27,000. Finally, Cantor Fitzgerald L. P. purchased a new position in BriaCell Therapeutics during the fourth quarter worth about $32,000. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $3.67 on Friday. BriaCell Therapeutics has a 52-week low of $3.33 and a 52-week high of $52.93. The stock’s 50-day simple moving average is $5.77 and its 200 day simple moving average is $9.61. The stock has a market capitalization of $13.61 million, a price-to-earnings ratio of -0.28 and a beta of 1.59.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, December 16th. The company reported ($3.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10). On average, research analysts forecast that BriaCell Therapeutics will post -2.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright increased their target price on BriaCell Therapeutics from $15.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.